SlideShare a Scribd company logo
Adichunchanagiri
Institute of Medical
Sciences
Chief Patron
Paramapoojya
Sri Sri Sri
Nirmalanandanatha
Mahaswamiji
Chief Advisor
Dr Shivaramu M.G.
Principal A.I.M.S.
Chief Editor
Dr Aliya Nusrath.
Professor & Head
Dept. of Biochemistry
Editorial Board
Dr. Rajeshwari A.
Assoc. Professor
Sri. Somashekar G.N.
Asst. Professor
Dr. Chikkanna D.
Asst. Professor
Dr Maithri C.M.
Asst. Professor
Dr Asha Rani N.
Asst. Professor
Members
Dr. Prathibha K.
Tutor cum PG
Dr Namitha D.
Tutor cum PG
Contact information:
biomedaims@gmail.com
Biomed
Dept of Biochemistry
___________________________________________________
News letter
VOLUME 1 ISSUE 3 JULY 2013
___________________________________________________
From Editor’s Desk
Greetings
With immense pleasure we are releasing the third
issue of Biomed. Medical field is ever growing with newer
trends. In this context we have tried to throw light on newer
protein frontiers in health and disease in this edition.
Many a changes have taken place in the department.
It was disheartening to let go of our senior technician Sri
Mahalinge Gowda after 25 years of his service. However as
it is said life goes on, we also had many a cause for
celebration. Our department was expanded with newly
furnished research laboratory and other facilities. Also we
congratulate and welcome the MCI grant for 150
admissions of undergraduates as well as the Government
approval of University status to our institution.
Send off party of Sri Mahalinge Gowda
First Row (From left to right): Dr Asha Rani,
Dr Maithri, Dr Rajeshwari A, Sri Mahalinge Gowda,
Dr Aliya Nusrath, Sri Somashekhar and
Dr Chikkanna
Second Row (From left to right): Sri Hongere Gowda, Sri
Yateesh, Sri Mahalinge Gowda,
Sri Ramesh, Sri Shankare Gowda and Sri Krishne Gowda
Saposin B deficiency
Arylsulfatase A deficiency results in Metachromatic leukodystrophy (MLD). There are three clinical
subtypes, which are primarily distinguished by age of onset, late-infantile MLD (50-60%), juvenile
MLD(20-30%) and adult MLD (15-20%). MLD is suspected in individuals with progressive neurological
functions and MRI evidence of leucodystrophy. MLD may be due to ARSA enzyme activity in leucocytes
less than 10% of normal controls. However assay of ARSA enzyme activity cannot distinguish between
MLD and ARSA pseudodeficiency, where ARSA enzyme activity is 5% to 20% of normal controls and does
not cause MLD. Thus the diagnosis of MLD must be confirmed by one or more tests like molecular testing
of the ARSA, the only gene in which mutation causes ARSA deficiency, urinary excretion of sulfatides and
presence of metachromatic lipid deposit in nervous tissue.
High prevalence of ARSA pseudodeficiency with low levels of ARSA enzyme activity is found in
association with many disorders and it is diagnosed with the neurodegenerative disorder is often consider
due to deficiency of ARSA activity. However schizophrenia depression, substance abuse, multiple sclerosis
and various forms of dementia frequently seen in general population may not be due to the low levels of
ARSA activity.
Saposin B is an activator protein, is required for the degradation of sulfatide by Arylsulfatase A
(ARSA) and hydrolysis of globotriaosylceramide and digalactosylceramide by α-galactosidases. Saposins
(A, B, C and D) are small glycoprotiens derived from the precursor protein prosaposin by proteolytic
cleavage. Prosaposin is 65-70KDa protein exists both as secretory protein as well as integral membrane
protein and as neurotropic activities. Deficiency of saposin due to gene defect results in the accumulation of
multiple sphingolipids leading to the complex sphingolipidosis with early fatal consequences. Saposin B
deficiency causes MLD like disorder due to the disrupted glycolipid degradation, MLD like clinical
presentation leukodystrophy on MRI, normal ARSA enzyme activity and excess urinary sulfatide excretion
or sulfatide storage. Diagnosis can be evaluated on depressed sulfatide degradation by culture cells,
immunochemical assessment of saposin B levels or sequence analysis of gene encoding saposin B.
Dr. Rajeshwari A Assoc. Professor, Biochemistry
Irisin
The benefit of exercise has been extensively studied and is the method for non-pharmacological
treatment of cardiovascular and metabolic diseases like diabetes mellitus, obesity etc. Exercise is known to
induce weight loss and improve glucose homeostasis. However, the molecular mechanism behind it
remained largely unexplained. In 2012, a hormone called Irisin named after Greek goddess iris, was
discovered by Bruce M Spigelmen et al which was found to be responsible for exercise induced weight loss
and improved glucose homeostasis. It is a PGC - 1α induced myokine, a 112 AA polypeptide secreted from
muscle into the bloodstream in response to exercise.
There are two types of adipose tissues in our body namely, white adipose tissue and brown adipose
tissue. The main function of white adipose tissue is to store fat whereas brown adipose tissue has non
shivering thermogenic properties due to expression of uncoupling protein – 1 and increased mitochondrial
content.
As per the molecular mechanism, exercise is the stimulus for release of PGC1α which is a co-
activator of PPAPγ (peroxisome proliferator activated receptor). This in turn stimulates the expression of
FNDC5 which in turn is proteolytically cleaved to release the active hormone Irisin. This Irisin has cell
surface receptors. It increases the expression of UCP1 and cidea mRNA, which causes the browning of
primarily subcutaneous and also of visceral adipose tissue and thereby inducing thermogenesis. So Irisin
causes white adipose tissue to get converted to brown adipose tissue and thereby reduction of insulin
resistance and improvement of glucose homeostasis. Hence it may be useful as anti-obesity treatment and
anti-diabetic treatment. Hence Irisin may be useful in the treatment of obesity, diabetes and metabolic
syndrome especially to people who cannot exercise because of physical limitations.
At present, all the effects of Irisin are seen in mice, because of its 100% sequence homology, it is
being assumed to have same effect in humans for whom clinical trials are being conducted.
Dr. Maithri C.M, Assistant Professor, Biochemistry
Sirtuin or Sir2 proteins
Sirtuin or Sir2 proteins are a class of proteins that possess either mono-ribosyltransferase, or deacylase
activity. The name Sir2 comes from the yeast gene 'silent mating-type information regulation 2',the gene
responsible for cellular regulation in yeast. Sirtuins have been implicated in influencing a wide range of
cellular processes like aging, transcription, apoptosis, inflammation and stress resistance, as well as energy
efficiency and alertness during low-calorie situations. Sirtuins can also control circadian clocks and
mitochondrial biogenesis. Mammals possess seven sirtuins (SIRT1-7) that occupy different subcellular
compartments such as the nucleus (SIRT1, -2, -6, -7), cytoplasm (SIRT1 and SIRT2) and the mitochondria
(SIRT3, -4 and -5).
Clinical significance
Sirtuin activity is inhibited by nicotinamide, which binds to a specific receptor site, so it is thought that
drugs that interfere with this binding should increase sirtuin activity. Development of new agents that would
specifically block the nicotinamide-binding site could provide an avenue for development of newer agents to
treat degenerative diseases such as cancer, Alzheimer's, diabetes, atherosclerosis, and gout.
Alzheimer's disease: SIRT1 deacetylates and coactivates the retinoic acid receptor beta that upregulates the
expression of alpha-secretase (ADAM10). Alpha-secretase in turn suppresses beta-amyloid production.
Furthermore, ADAM10 activation by SIRT1 also induces the Notch signaling pathway, which is known to
repair neuronal damage in the brain.
Aging: Preliminary studies with resveratrol, a possible SIRT1 activator, have led some scientists to
speculate that resveratrol may extend lifespan. Further experiments conducted by Rafael de Cabo et al.
showed that resveratrol-mimicking drugs such as SRT1720 could extend the lifespan of obese mice by 44%.
Comparable molecules are now undergoing clinical trials in humans.
Dr. Asha Rani N, Assistant Professor, Biochemistry
Visfatin
Visfatin is a newly discovered adipocyte hormone with a direct relationship between plasma visfatin level
and type 2 diabetes mellitus. Also known as Nicotinamide phosphoribosyltransferase (NAmPRTase or
Nampt) as pre-B-cell colony-enhancing factor 1 (PBEF1) .It is an enzyme that in humans is encoded by the
PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation
and inhibits neutrophil apoptosis.
NAmPRTase catalyzes the following chemical reaction:
Nicotinamide D-ribonucleotide + diphosphate -------Nicotinamide + 5-phospho-alpha-D-ribose 1-
diphosphate
This enzyme belongs to the family of glycosyltransferases, to be specific, the pentosyltransferases. This
enzyme participates in nicotinate and nicotinamide metabolism.
Function: The protein is an adipokine that is localized to the bloodstream It is an endocrine, autocrine as
well as paracrine peptide with many functions including enhancement of cell proliferation, biosynthesis of
nicotinamide mono- and dinucleotide and hypoglycaemic effect, including the promotion of vascular smooth
muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has
insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity. Visfatin binds to the
insulin receptor at a site distinct from that of insulin and causes hypoglycaemia by reducing glucose release
from liver cells and stimulating glucose utilization in adipocytes and myocytes. The protein is highly
expressed in visceral fat and serum levels of the protein correlate with obesity. This has also been identified
in many tissues and organs including the brain, kidney, lung, spleen and testis but preferentially expressed in
visceral adipose tissue Visfatin is up regulated by hypoxia, inflammation and hyperglycaemia and
downregulated by insulin, somatostatin and statins.
Dr.Prathibha K Postgraduate, Biochemistry
Fun and Learn
Biomed Crossword
(Crossword on biochemical basis of diseases)
1 2 3 4 5
6 7
8 9
10
11 12 13
14 15
16 17
18
19 20 21
22
23
24
Across
1. X-linked Mucopolysacchroidosis (7)
7. Disease due to trinucleotide CAG expansion (6)
8. A disease common in hilly areas (6)
11. Also called as Forbe’s disease (5)
12. An underlying disease for all organ complications (8)
16. A disease with four D’s (8)
18. After the age of 40 years, you need to watch for this
disease (5)
20. ___ syndrome in which there is hypoglycaemia and
dicarboxylic aciduria in infants (4) (Abbreviation)
22. A disease due to protein misfolding (5)
23. A disease with burnt sugar urine (4) (Abbreviation)
24. Accumulation of GM2 occurs in this disease (3,5)
Down
2. ___ syndrome with trisomy 18
3. First disease with gene therapy (4)
(Abbreviation)
4. Many great personalities Newton,
Darwin etc suffered from this disease
(4)
5. A disease which is pronoun for
women (4)
6. A disease with charlie chaplin gait
(14)
9. Phosphofructokinase deficiency
disease (6)
10. A group of sexually transmitted
diseases (3)
13. Limeys did not suffer from this
disease (6)
14. β- Glucoronidase deficiency (4)
15. A primary dyslipoproteinemis
with low HDL (7)
16. Nutritional disorders (3)
(Abbreviation)
17. Dietary consumption of
methylated fatty acids leads to this
neurological disorder (7)
19. _______ eye disease (4)
21. About 20 % inmates of lunatic
asylum may have this disease (3)
(Abbreviation)
By Dr Aliya Nusrath
Prof and HOD, Biochemistry.
Answers will be given in next
issue
{Answers of previous issue
Across: 2.Collgen 7.Uracil. 9. BAL 10 Page
11.ETC 12.Ligase 13.Iodine 14.CO 15.Ryle
16.Laminin 19.Niacin 21.Leptin 23.STD
24.Peptide 25.Orotate 27.Starch 29.RE
30.Myosin 31.Phenol
Down: 1.Fiber 2.Calcium 3.Lipid 4.Arginine
5.Nucleotide 6.Sanger 8.Insulin 17.Acetone
18.Intron 19.NTP 20.Citrate 22.NSAIDs
26.Exon 27.SNP 2
QUOTE
“Research is to see what everybody has seen and to think what nobody else has thought”.
Albert Szent-Gyorgyi.
Biochemistry dept news letter july_13

More Related Content

What's hot

Revisiting Caloric Restriction as Therapeutic Strategy for MetS, T2DM and Obe...
Revisiting Caloric Restriction as Therapeutic Strategy for MetS, T2DM and Obe...Revisiting Caloric Restriction as Therapeutic Strategy for MetS, T2DM and Obe...
Revisiting Caloric Restriction as Therapeutic Strategy for MetS, T2DM and Obe...
Vinod Nikhra
 
Pores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapyPores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapy
Osama Almaraghi
 
Metformin presentation sigma xi
Metformin presentation sigma xiMetformin presentation sigma xi
Metformin presentation sigma xi
Laceyg92
 
GLP-1 RA and Cardiovascular Outcomes
GLP-1 RA and Cardiovascular OutcomesGLP-1 RA and Cardiovascular Outcomes
GLP-1 RA and Cardiovascular Outcomes
Sachpreet Bajaj
 
Amylin aggregation in type2 diabetes
Amylin aggregation in type2 diabetesAmylin aggregation in type2 diabetes
Amylin aggregation in type2 diabetes
BalakrishnaLakavath
 
Ueda2016 symposium - glp-1 story,a closer look -yehia ghanem
Ueda2016 symposium - glp-1 story,a closer look -yehia ghanemUeda2016 symposium - glp-1 story,a closer look -yehia ghanem
Ueda2016 symposium - glp-1 story,a closer look -yehia ghanem
ueda2015
 
COMPARATIVE ASSESSMENT OF THE EEFFECT OF ARGINASE INHIBITOR L-NORVALINE AND M...
COMPARATIVE ASSESSMENT OF THE EEFFECT OF ARGINASE INHIBITOR L-NORVALINE AND M...COMPARATIVE ASSESSMENT OF THE EEFFECT OF ARGINASE INHIBITOR L-NORVALINE AND M...
COMPARATIVE ASSESSMENT OF THE EEFFECT OF ARGINASE INHIBITOR L-NORVALINE AND M...
ShubhamBaliyan13
 
SGLTI2 Inhibitor by Dr Shahjada Selim
SGLTI2 Inhibitor by Dr Shahjada SelimSGLTI2 Inhibitor by Dr Shahjada Selim
SGLTI2 Inhibitor by Dr Shahjada Selim
Bangabandhu Sheikh Mujib Medical University
 
Ueda2015 type 2 dm management dr.mesbah kamel
Ueda2015  type 2 dm management dr.mesbah kamelUeda2015  type 2 dm management dr.mesbah kamel
Ueda2015 type 2 dm management dr.mesbah kamelueda2015
 
URC Final Poster Draft
URC Final Poster DraftURC Final Poster Draft
URC Final Poster DraftSeth Burgess
 
Achieving Treatment Outcome With DPP4i for Diabetic Patient "Efficacy Beyond ...
Achieving Treatment Outcome With DPP4i for Diabetic Patient "Efficacy Beyond ...Achieving Treatment Outcome With DPP4i for Diabetic Patient "Efficacy Beyond ...
Achieving Treatment Outcome With DPP4i for Diabetic Patient "Efficacy Beyond ...
Suharti Wairagya
 
Ueda2016 symposium -t2 dm management - lobna el toony
Ueda2016 symposium -t2 dm management  - lobna el toonyUeda2016 symposium -t2 dm management  - lobna el toony
Ueda2016 symposium -t2 dm management - lobna el toony
ueda2015
 
Diabetes updates, DPP4 inhitors and Ramadan and DM
Diabetes  updates, DPP4 inhitors and Ramadan and DMDiabetes  updates, DPP4 inhitors and Ramadan and DM
Diabetes updates, DPP4 inhitors and Ramadan and DM
Rajat Biswas
 
GLUTAMINE IN NUTRITIONAL MANANGMENT
GLUTAMINE IN NUTRITIONAL MANANGMENTGLUTAMINE IN NUTRITIONAL MANANGMENT
GLUTAMINE IN NUTRITIONAL MANANGMENT
PhD student of nutritional sciences
 
ueda2011 ealier insulinization-d.abbas
ueda2011 ealier insulinization-d.abbasueda2011 ealier insulinization-d.abbas
ueda2011 ealier insulinization-d.abbas
ueda2015
 
Diabetes Asia
Diabetes AsiaDiabetes Asia
Diabetes and application in OMFS
Diabetes and application in OMFSDiabetes and application in OMFS
Diabetes and application in OMFS
Savita Sahu
 
Type 2 DM ; Metformin Best Partner
Type 2 DM ; Metformin Best PartnerType 2 DM ; Metformin Best Partner
Type 2 DM ; Metformin Best Partner
Mohammad Othman Daoud
 

What's hot (20)

Revisiting Caloric Restriction as Therapeutic Strategy for MetS, T2DM and Obe...
Revisiting Caloric Restriction as Therapeutic Strategy for MetS, T2DM and Obe...Revisiting Caloric Restriction as Therapeutic Strategy for MetS, T2DM and Obe...
Revisiting Caloric Restriction as Therapeutic Strategy for MetS, T2DM and Obe...
 
Pores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapyPores and cores of new anti diabetic therapy
Pores and cores of new anti diabetic therapy
 
Metformin presentation sigma xi
Metformin presentation sigma xiMetformin presentation sigma xi
Metformin presentation sigma xi
 
GLP-1 RA and Cardiovascular Outcomes
GLP-1 RA and Cardiovascular OutcomesGLP-1 RA and Cardiovascular Outcomes
GLP-1 RA and Cardiovascular Outcomes
 
Amylin aggregation in type2 diabetes
Amylin aggregation in type2 diabetesAmylin aggregation in type2 diabetes
Amylin aggregation in type2 diabetes
 
Ueda2016 symposium - glp-1 story,a closer look -yehia ghanem
Ueda2016 symposium - glp-1 story,a closer look -yehia ghanemUeda2016 symposium - glp-1 story,a closer look -yehia ghanem
Ueda2016 symposium - glp-1 story,a closer look -yehia ghanem
 
COMPARATIVE ASSESSMENT OF THE EEFFECT OF ARGINASE INHIBITOR L-NORVALINE AND M...
COMPARATIVE ASSESSMENT OF THE EEFFECT OF ARGINASE INHIBITOR L-NORVALINE AND M...COMPARATIVE ASSESSMENT OF THE EEFFECT OF ARGINASE INHIBITOR L-NORVALINE AND M...
COMPARATIVE ASSESSMENT OF THE EEFFECT OF ARGINASE INHIBITOR L-NORVALINE AND M...
 
演示文稿1
演示文稿1演示文稿1
演示文稿1
 
presentation01_internet
presentation01_internetpresentation01_internet
presentation01_internet
 
SGLTI2 Inhibitor by Dr Shahjada Selim
SGLTI2 Inhibitor by Dr Shahjada SelimSGLTI2 Inhibitor by Dr Shahjada Selim
SGLTI2 Inhibitor by Dr Shahjada Selim
 
Ueda2015 type 2 dm management dr.mesbah kamel
Ueda2015  type 2 dm management dr.mesbah kamelUeda2015  type 2 dm management dr.mesbah kamel
Ueda2015 type 2 dm management dr.mesbah kamel
 
URC Final Poster Draft
URC Final Poster DraftURC Final Poster Draft
URC Final Poster Draft
 
Achieving Treatment Outcome With DPP4i for Diabetic Patient "Efficacy Beyond ...
Achieving Treatment Outcome With DPP4i for Diabetic Patient "Efficacy Beyond ...Achieving Treatment Outcome With DPP4i for Diabetic Patient "Efficacy Beyond ...
Achieving Treatment Outcome With DPP4i for Diabetic Patient "Efficacy Beyond ...
 
Ueda2016 symposium -t2 dm management - lobna el toony
Ueda2016 symposium -t2 dm management  - lobna el toonyUeda2016 symposium -t2 dm management  - lobna el toony
Ueda2016 symposium -t2 dm management - lobna el toony
 
Diabetes updates, DPP4 inhitors and Ramadan and DM
Diabetes  updates, DPP4 inhitors and Ramadan and DMDiabetes  updates, DPP4 inhitors and Ramadan and DM
Diabetes updates, DPP4 inhitors and Ramadan and DM
 
GLUTAMINE IN NUTRITIONAL MANANGMENT
GLUTAMINE IN NUTRITIONAL MANANGMENTGLUTAMINE IN NUTRITIONAL MANANGMENT
GLUTAMINE IN NUTRITIONAL MANANGMENT
 
ueda2011 ealier insulinization-d.abbas
ueda2011 ealier insulinization-d.abbasueda2011 ealier insulinization-d.abbas
ueda2011 ealier insulinization-d.abbas
 
Diabetes Asia
Diabetes AsiaDiabetes Asia
Diabetes Asia
 
Diabetes and application in OMFS
Diabetes and application in OMFSDiabetes and application in OMFS
Diabetes and application in OMFS
 
Type 2 DM ; Metformin Best Partner
Type 2 DM ; Metformin Best PartnerType 2 DM ; Metformin Best Partner
Type 2 DM ; Metformin Best Partner
 

Similar to Biochemistry dept news letter july_13

Biochemistry dept news letter july_12
Biochemistry dept news letter july_12Biochemistry dept news letter july_12
Biochemistry dept news letter july_12hgkswamy
 
Alzheimer disease
Alzheimer diseaseAlzheimer disease
Alzheimer disease
dr_ekbalabohashem
 
Signaling in diabetes
Signaling in diabetesSignaling in diabetes
Signaling in diabetes
mohsen koolivand
 
Resveratrol, Caloric Restriction and Longevity in Human Mitochondrial Dysfunc...
Resveratrol, Caloric Restriction and Longevity in Human Mitochondrial Dysfunc...Resveratrol, Caloric Restriction and Longevity in Human Mitochondrial Dysfunc...
Resveratrol, Caloric Restriction and Longevity in Human Mitochondrial Dysfunc...
Ayetenew Abita Desa
 
41392_2022_Article_1149.pdf
41392_2022_Article_1149.pdf41392_2022_Article_1149.pdf
41392_2022_Article_1149.pdf
RodrigoDalia1
 
Polycystic ovary syndrome (pcos) .
Polycystic ovary syndrome (pcos) .Polycystic ovary syndrome (pcos) .
Polycystic ovary syndrome (pcos) .
dr_ekbalabohashem
 
A mild reduction of food intake slows disease progression in an orthologous m...
A mild reduction of food intake slows disease progression in an orthologous m...A mild reduction of food intake slows disease progression in an orthologous m...
A mild reduction of food intake slows disease progression in an orthologous m...Mina Rezaei
 
GLP1 ANALOGUES- BEYOND DIABETES.pptx
GLP1 ANALOGUES- BEYOND DIABETES.pptxGLP1 ANALOGUES- BEYOND DIABETES.pptx
GLP1 ANALOGUES- BEYOND DIABETES.pptx
Sayan Chatterjee
 
Pioglitazone
PioglitazonePioglitazone
Pioglitazone
BALASUBRAMANIAM IYER
 
Herbal therapies for type 2 diabetes mellitus
Herbal therapies for type 2 diabetes mellitusHerbal therapies for type 2 diabetes mellitus
Herbal therapies for type 2 diabetes mellitus
Dwie Craph
 
Hunter Syndrome A Case Report
Hunter Syndrome A Case ReportHunter Syndrome A Case Report
Hunter Syndrome A Case Report
ijtsrd
 
Biochemistry dept. news letter _jan_2014
Biochemistry dept. news letter _jan_2014Biochemistry dept. news letter _jan_2014
Biochemistry dept. news letter _jan_2014hgkswamy
 
METABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptxMETABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptx
mbaeyigoddey
 
the novel biomarker in diabetes.
the novel biomarker in diabetes.the novel biomarker in diabetes.
the novel biomarker in diabetes.
Dr. Raju Niraula
 
antidiabetic and hypoglycemic effect of isolated flavonoids from ficus racemo...
antidiabetic and hypoglycemic effect of isolated flavonoids from ficus racemo...antidiabetic and hypoglycemic effect of isolated flavonoids from ficus racemo...
antidiabetic and hypoglycemic effect of isolated flavonoids from ficus racemo...
Ghanendra Kumar
 

Similar to Biochemistry dept news letter july_13 (20)

Biochemistry dept news letter july_12
Biochemistry dept news letter july_12Biochemistry dept news letter july_12
Biochemistry dept news letter july_12
 
Awakush
AwakushAwakush
Awakush
 
Alzheimer disease
Alzheimer diseaseAlzheimer disease
Alzheimer disease
 
Signaling in diabetes
Signaling in diabetesSignaling in diabetes
Signaling in diabetes
 
Journal club
Journal clubJournal club
Journal club
 
Resveratrol, Caloric Restriction and Longevity in Human Mitochondrial Dysfunc...
Resveratrol, Caloric Restriction and Longevity in Human Mitochondrial Dysfunc...Resveratrol, Caloric Restriction and Longevity in Human Mitochondrial Dysfunc...
Resveratrol, Caloric Restriction and Longevity in Human Mitochondrial Dysfunc...
 
41392_2022_Article_1149.pdf
41392_2022_Article_1149.pdf41392_2022_Article_1149.pdf
41392_2022_Article_1149.pdf
 
Polycystic ovary syndrome (pcos) .
Polycystic ovary syndrome (pcos) .Polycystic ovary syndrome (pcos) .
Polycystic ovary syndrome (pcos) .
 
A mild reduction of food intake slows disease progression in an orthologous m...
A mild reduction of food intake slows disease progression in an orthologous m...A mild reduction of food intake slows disease progression in an orthologous m...
A mild reduction of food intake slows disease progression in an orthologous m...
 
GLP1 ANALOGUES- BEYOND DIABETES.pptx
GLP1 ANALOGUES- BEYOND DIABETES.pptxGLP1 ANALOGUES- BEYOND DIABETES.pptx
GLP1 ANALOGUES- BEYOND DIABETES.pptx
 
Obesity ppt 2
Obesity ppt 2Obesity ppt 2
Obesity ppt 2
 
Pioglitazone
PioglitazonePioglitazone
Pioglitazone
 
Poloz_Obesity_CDDis_2015
Poloz_Obesity_CDDis_2015Poloz_Obesity_CDDis_2015
Poloz_Obesity_CDDis_2015
 
spilman rapamycin mTOR
spilman rapamycin mTORspilman rapamycin mTOR
spilman rapamycin mTOR
 
Herbal therapies for type 2 diabetes mellitus
Herbal therapies for type 2 diabetes mellitusHerbal therapies for type 2 diabetes mellitus
Herbal therapies for type 2 diabetes mellitus
 
Hunter Syndrome A Case Report
Hunter Syndrome A Case ReportHunter Syndrome A Case Report
Hunter Syndrome A Case Report
 
Biochemistry dept. news letter _jan_2014
Biochemistry dept. news letter _jan_2014Biochemistry dept. news letter _jan_2014
Biochemistry dept. news letter _jan_2014
 
METABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptxMETABOLIC SYNDROME.pptx
METABOLIC SYNDROME.pptx
 
the novel biomarker in diabetes.
the novel biomarker in diabetes.the novel biomarker in diabetes.
the novel biomarker in diabetes.
 
antidiabetic and hypoglycemic effect of isolated flavonoids from ficus racemo...
antidiabetic and hypoglycemic effect of isolated flavonoids from ficus racemo...antidiabetic and hypoglycemic effect of isolated flavonoids from ficus racemo...
antidiabetic and hypoglycemic effect of isolated flavonoids from ficus racemo...
 

More from hgkswamy

Biochemistry dept news letter _sept_11
Biochemistry dept news letter _sept_11Biochemistry dept news letter _sept_11
Biochemistry dept news letter _sept_11hgkswamy
 
Biochemistry dept news letter july__2014
Biochemistry dept news letter july__2014Biochemistry dept news letter july__2014
Biochemistry dept news letter july__2014hgkswamy
 
Biochemistry dept news letter _sept_11
Biochemistry dept news letter _sept_11Biochemistry dept news letter _sept_11
Biochemistry dept news letter _sept_11hgkswamy
 
Anatomy mbbs rguhs qp1999 to 2001 m old paper
Anatomy mbbs rguhs qp1999 to 2001 m old paperAnatomy mbbs rguhs qp1999 to 2001 m old paper
Anatomy mbbs rguhs qp1999 to 2001 m old paperhgkswamy
 
Anatomy mbbs rguhs qp feb 2007 to junejuly 2011
Anatomy mbbs rguhs qp feb 2007 to junejuly 2011Anatomy mbbs rguhs qp feb 2007 to junejuly 2011
Anatomy mbbs rguhs qp feb 2007 to junejuly 2011hgkswamy
 
Anatomy mbbs rguhs qp 2005 to 2006 qp
Anatomy mbbs rguhs qp 2005 to 2006 qpAnatomy mbbs rguhs qp 2005 to 2006 qp
Anatomy mbbs rguhs qp 2005 to 2006 qphgkswamy
 
ANATOMY MBBS RGUHS QP 1999 to 2001 m old paper
ANATOMY MBBS RGUHS QP 1999 to 2001 m old paperANATOMY MBBS RGUHS QP 1999 to 2001 m old paper
ANATOMY MBBS RGUHS QP 1999 to 2001 m old paperhgkswamy
 
ANATOMY MBBS RGUS QP 1998 onwards
ANATOMY MBBS RGUS QP 1998 onwardsANATOMY MBBS RGUS QP 1998 onwards
ANATOMY MBBS RGUS QP 1998 onwards
hgkswamy
 
U.g. anatomy q.p june 2014
U.g. anatomy q.p june 2014U.g. anatomy q.p june 2014
U.g. anatomy q.p june 2014
hgkswamy
 

More from hgkswamy (9)

Biochemistry dept news letter _sept_11
Biochemistry dept news letter _sept_11Biochemistry dept news letter _sept_11
Biochemistry dept news letter _sept_11
 
Biochemistry dept news letter july__2014
Biochemistry dept news letter july__2014Biochemistry dept news letter july__2014
Biochemistry dept news letter july__2014
 
Biochemistry dept news letter _sept_11
Biochemistry dept news letter _sept_11Biochemistry dept news letter _sept_11
Biochemistry dept news letter _sept_11
 
Anatomy mbbs rguhs qp1999 to 2001 m old paper
Anatomy mbbs rguhs qp1999 to 2001 m old paperAnatomy mbbs rguhs qp1999 to 2001 m old paper
Anatomy mbbs rguhs qp1999 to 2001 m old paper
 
Anatomy mbbs rguhs qp feb 2007 to junejuly 2011
Anatomy mbbs rguhs qp feb 2007 to junejuly 2011Anatomy mbbs rguhs qp feb 2007 to junejuly 2011
Anatomy mbbs rguhs qp feb 2007 to junejuly 2011
 
Anatomy mbbs rguhs qp 2005 to 2006 qp
Anatomy mbbs rguhs qp 2005 to 2006 qpAnatomy mbbs rguhs qp 2005 to 2006 qp
Anatomy mbbs rguhs qp 2005 to 2006 qp
 
ANATOMY MBBS RGUHS QP 1999 to 2001 m old paper
ANATOMY MBBS RGUHS QP 1999 to 2001 m old paperANATOMY MBBS RGUHS QP 1999 to 2001 m old paper
ANATOMY MBBS RGUHS QP 1999 to 2001 m old paper
 
ANATOMY MBBS RGUS QP 1998 onwards
ANATOMY MBBS RGUS QP 1998 onwardsANATOMY MBBS RGUS QP 1998 onwards
ANATOMY MBBS RGUS QP 1998 onwards
 
U.g. anatomy q.p june 2014
U.g. anatomy q.p june 2014U.g. anatomy q.p june 2014
U.g. anatomy q.p june 2014
 

Biochemistry dept news letter july_13

  • 1. Adichunchanagiri Institute of Medical Sciences Chief Patron Paramapoojya Sri Sri Sri Nirmalanandanatha Mahaswamiji Chief Advisor Dr Shivaramu M.G. Principal A.I.M.S. Chief Editor Dr Aliya Nusrath. Professor & Head Dept. of Biochemistry Editorial Board Dr. Rajeshwari A. Assoc. Professor Sri. Somashekar G.N. Asst. Professor Dr. Chikkanna D. Asst. Professor Dr Maithri C.M. Asst. Professor Dr Asha Rani N. Asst. Professor Members Dr. Prathibha K. Tutor cum PG Dr Namitha D. Tutor cum PG Contact information: biomedaims@gmail.com Biomed Dept of Biochemistry ___________________________________________________ News letter VOLUME 1 ISSUE 3 JULY 2013 ___________________________________________________ From Editor’s Desk Greetings With immense pleasure we are releasing the third issue of Biomed. Medical field is ever growing with newer trends. In this context we have tried to throw light on newer protein frontiers in health and disease in this edition. Many a changes have taken place in the department. It was disheartening to let go of our senior technician Sri Mahalinge Gowda after 25 years of his service. However as it is said life goes on, we also had many a cause for celebration. Our department was expanded with newly furnished research laboratory and other facilities. Also we congratulate and welcome the MCI grant for 150 admissions of undergraduates as well as the Government approval of University status to our institution. Send off party of Sri Mahalinge Gowda First Row (From left to right): Dr Asha Rani, Dr Maithri, Dr Rajeshwari A, Sri Mahalinge Gowda, Dr Aliya Nusrath, Sri Somashekhar and Dr Chikkanna Second Row (From left to right): Sri Hongere Gowda, Sri Yateesh, Sri Mahalinge Gowda, Sri Ramesh, Sri Shankare Gowda and Sri Krishne Gowda
  • 2. Saposin B deficiency Arylsulfatase A deficiency results in Metachromatic leukodystrophy (MLD). There are three clinical subtypes, which are primarily distinguished by age of onset, late-infantile MLD (50-60%), juvenile MLD(20-30%) and adult MLD (15-20%). MLD is suspected in individuals with progressive neurological functions and MRI evidence of leucodystrophy. MLD may be due to ARSA enzyme activity in leucocytes less than 10% of normal controls. However assay of ARSA enzyme activity cannot distinguish between MLD and ARSA pseudodeficiency, where ARSA enzyme activity is 5% to 20% of normal controls and does not cause MLD. Thus the diagnosis of MLD must be confirmed by one or more tests like molecular testing of the ARSA, the only gene in which mutation causes ARSA deficiency, urinary excretion of sulfatides and presence of metachromatic lipid deposit in nervous tissue. High prevalence of ARSA pseudodeficiency with low levels of ARSA enzyme activity is found in association with many disorders and it is diagnosed with the neurodegenerative disorder is often consider due to deficiency of ARSA activity. However schizophrenia depression, substance abuse, multiple sclerosis and various forms of dementia frequently seen in general population may not be due to the low levels of ARSA activity. Saposin B is an activator protein, is required for the degradation of sulfatide by Arylsulfatase A (ARSA) and hydrolysis of globotriaosylceramide and digalactosylceramide by α-galactosidases. Saposins (A, B, C and D) are small glycoprotiens derived from the precursor protein prosaposin by proteolytic cleavage. Prosaposin is 65-70KDa protein exists both as secretory protein as well as integral membrane protein and as neurotropic activities. Deficiency of saposin due to gene defect results in the accumulation of multiple sphingolipids leading to the complex sphingolipidosis with early fatal consequences. Saposin B deficiency causes MLD like disorder due to the disrupted glycolipid degradation, MLD like clinical presentation leukodystrophy on MRI, normal ARSA enzyme activity and excess urinary sulfatide excretion or sulfatide storage. Diagnosis can be evaluated on depressed sulfatide degradation by culture cells, immunochemical assessment of saposin B levels or sequence analysis of gene encoding saposin B. Dr. Rajeshwari A Assoc. Professor, Biochemistry Irisin The benefit of exercise has been extensively studied and is the method for non-pharmacological treatment of cardiovascular and metabolic diseases like diabetes mellitus, obesity etc. Exercise is known to induce weight loss and improve glucose homeostasis. However, the molecular mechanism behind it remained largely unexplained. In 2012, a hormone called Irisin named after Greek goddess iris, was discovered by Bruce M Spigelmen et al which was found to be responsible for exercise induced weight loss and improved glucose homeostasis. It is a PGC - 1α induced myokine, a 112 AA polypeptide secreted from muscle into the bloodstream in response to exercise. There are two types of adipose tissues in our body namely, white adipose tissue and brown adipose tissue. The main function of white adipose tissue is to store fat whereas brown adipose tissue has non shivering thermogenic properties due to expression of uncoupling protein – 1 and increased mitochondrial content. As per the molecular mechanism, exercise is the stimulus for release of PGC1α which is a co- activator of PPAPγ (peroxisome proliferator activated receptor). This in turn stimulates the expression of FNDC5 which in turn is proteolytically cleaved to release the active hormone Irisin. This Irisin has cell surface receptors. It increases the expression of UCP1 and cidea mRNA, which causes the browning of primarily subcutaneous and also of visceral adipose tissue and thereby inducing thermogenesis. So Irisin causes white adipose tissue to get converted to brown adipose tissue and thereby reduction of insulin resistance and improvement of glucose homeostasis. Hence it may be useful as anti-obesity treatment and anti-diabetic treatment. Hence Irisin may be useful in the treatment of obesity, diabetes and metabolic syndrome especially to people who cannot exercise because of physical limitations. At present, all the effects of Irisin are seen in mice, because of its 100% sequence homology, it is being assumed to have same effect in humans for whom clinical trials are being conducted. Dr. Maithri C.M, Assistant Professor, Biochemistry
  • 3. Sirtuin or Sir2 proteins Sirtuin or Sir2 proteins are a class of proteins that possess either mono-ribosyltransferase, or deacylase activity. The name Sir2 comes from the yeast gene 'silent mating-type information regulation 2',the gene responsible for cellular regulation in yeast. Sirtuins have been implicated in influencing a wide range of cellular processes like aging, transcription, apoptosis, inflammation and stress resistance, as well as energy efficiency and alertness during low-calorie situations. Sirtuins can also control circadian clocks and mitochondrial biogenesis. Mammals possess seven sirtuins (SIRT1-7) that occupy different subcellular compartments such as the nucleus (SIRT1, -2, -6, -7), cytoplasm (SIRT1 and SIRT2) and the mitochondria (SIRT3, -4 and -5). Clinical significance Sirtuin activity is inhibited by nicotinamide, which binds to a specific receptor site, so it is thought that drugs that interfere with this binding should increase sirtuin activity. Development of new agents that would specifically block the nicotinamide-binding site could provide an avenue for development of newer agents to treat degenerative diseases such as cancer, Alzheimer's, diabetes, atherosclerosis, and gout. Alzheimer's disease: SIRT1 deacetylates and coactivates the retinoic acid receptor beta that upregulates the expression of alpha-secretase (ADAM10). Alpha-secretase in turn suppresses beta-amyloid production. Furthermore, ADAM10 activation by SIRT1 also induces the Notch signaling pathway, which is known to repair neuronal damage in the brain. Aging: Preliminary studies with resveratrol, a possible SIRT1 activator, have led some scientists to speculate that resveratrol may extend lifespan. Further experiments conducted by Rafael de Cabo et al. showed that resveratrol-mimicking drugs such as SRT1720 could extend the lifespan of obese mice by 44%. Comparable molecules are now undergoing clinical trials in humans. Dr. Asha Rani N, Assistant Professor, Biochemistry Visfatin Visfatin is a newly discovered adipocyte hormone with a direct relationship between plasma visfatin level and type 2 diabetes mellitus. Also known as Nicotinamide phosphoribosyltransferase (NAmPRTase or Nampt) as pre-B-cell colony-enhancing factor 1 (PBEF1) .It is an enzyme that in humans is encoded by the PBEF1 gene. This protein has also been reported to be a cytokine (PBEF) that promotes B cell maturation and inhibits neutrophil apoptosis. NAmPRTase catalyzes the following chemical reaction: Nicotinamide D-ribonucleotide + diphosphate -------Nicotinamide + 5-phospho-alpha-D-ribose 1- diphosphate This enzyme belongs to the family of glycosyltransferases, to be specific, the pentosyltransferases. This enzyme participates in nicotinate and nicotinamide metabolism. Function: The protein is an adipokine that is localized to the bloodstream It is an endocrine, autocrine as well as paracrine peptide with many functions including enhancement of cell proliferation, biosynthesis of nicotinamide mono- and dinucleotide and hypoglycaemic effect, including the promotion of vascular smooth muscle cell maturation and inhibition of neutrophil apoptosis. It also activates insulin receptor and has insulin-mimetic effects, lowering blood glucose and improving insulin sensitivity. Visfatin binds to the insulin receptor at a site distinct from that of insulin and causes hypoglycaemia by reducing glucose release from liver cells and stimulating glucose utilization in adipocytes and myocytes. The protein is highly expressed in visceral fat and serum levels of the protein correlate with obesity. This has also been identified in many tissues and organs including the brain, kidney, lung, spleen and testis but preferentially expressed in visceral adipose tissue Visfatin is up regulated by hypoxia, inflammation and hyperglycaemia and downregulated by insulin, somatostatin and statins. Dr.Prathibha K Postgraduate, Biochemistry
  • 4. Fun and Learn Biomed Crossword (Crossword on biochemical basis of diseases) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Across 1. X-linked Mucopolysacchroidosis (7) 7. Disease due to trinucleotide CAG expansion (6) 8. A disease common in hilly areas (6) 11. Also called as Forbe’s disease (5) 12. An underlying disease for all organ complications (8) 16. A disease with four D’s (8) 18. After the age of 40 years, you need to watch for this disease (5) 20. ___ syndrome in which there is hypoglycaemia and dicarboxylic aciduria in infants (4) (Abbreviation) 22. A disease due to protein misfolding (5) 23. A disease with burnt sugar urine (4) (Abbreviation) 24. Accumulation of GM2 occurs in this disease (3,5) Down 2. ___ syndrome with trisomy 18 3. First disease with gene therapy (4) (Abbreviation) 4. Many great personalities Newton, Darwin etc suffered from this disease (4) 5. A disease which is pronoun for women (4) 6. A disease with charlie chaplin gait (14) 9. Phosphofructokinase deficiency disease (6) 10. A group of sexually transmitted diseases (3) 13. Limeys did not suffer from this disease (6) 14. β- Glucoronidase deficiency (4) 15. A primary dyslipoproteinemis with low HDL (7) 16. Nutritional disorders (3) (Abbreviation) 17. Dietary consumption of methylated fatty acids leads to this neurological disorder (7) 19. _______ eye disease (4) 21. About 20 % inmates of lunatic asylum may have this disease (3) (Abbreviation) By Dr Aliya Nusrath Prof and HOD, Biochemistry. Answers will be given in next issue {Answers of previous issue Across: 2.Collgen 7.Uracil. 9. BAL 10 Page 11.ETC 12.Ligase 13.Iodine 14.CO 15.Ryle 16.Laminin 19.Niacin 21.Leptin 23.STD 24.Peptide 25.Orotate 27.Starch 29.RE 30.Myosin 31.Phenol Down: 1.Fiber 2.Calcium 3.Lipid 4.Arginine 5.Nucleotide 6.Sanger 8.Insulin 17.Acetone 18.Intron 19.NTP 20.Citrate 22.NSAIDs 26.Exon 27.SNP 2 QUOTE “Research is to see what everybody has seen and to think what nobody else has thought”. Albert Szent-Gyorgyi.